Pharmacogenetics of acute lymphoblastic leukemia treatment response

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 15, 2007, Pages 2519-2531

  Cunningham, Lea ^a   Aplenc, Richard ^b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Acute lymphoblastic leukemia; Outcome; Pharmacogenetic; Single nucleotide polymorphism

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALKYLATING AGENT; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CARBON; CYTOCHROME P450 1A1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DAUNORUBICIN; ENZYME; EPIPODOPHYLLOTOXIN; ETOPOSIDE; FOLIC ACID; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; INTERLEUKIN 10; MACROPHAGE INFLAMMATORY PROTEIN; MERCAPTOPURINE; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; PREDNISONE; REDUCED FOLATE CARRIER; THIOPURINE METHYLTRANSFERASE; THYMIDYLATE SYNTHASE; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; VINCA ALKALOID; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; BLOOD TOXICITY; CHEMOTHERAPY INDUCED EMESIS; CHILDHOOD CANCER; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TRANSPORT; DRUG TREATMENT FAILURE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; IMMUNOSURVEILLANCE; LEUKEMIA RELAPSE; LEUKOPENIA; LIVER TOXICITY; MEDICAL LITERATURE; MUCOSA INFLAMMATION; NEUROTOXICITY; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PHARMACOGENETICS; PREDICTION; PROGNOSIS; REVIEW; RISK FACTOR; SECOND CANCER; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; PHARMACOGENETICS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TREATMENT OUTCOME;

EID: 35648982482     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.15.2519     Document Type: Review

References (87)

1. PUI, CH, SANDLUND JT, PEI D et al.: Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood (2004) 104(9):2690-2696.
2. RELLING MV, DERVIEUX T: Pharmacogenetics and cancer therapy. Nat. Rev. Cancer (2001) 1(2):99-108.
3. CARROLL WL, RAETZ EA: Building better therapy for children with acute lymphoblastic leukemia. Cancer Cell (2005) 7(4):289-291.
4. CHENG Q, YANG W, RAIMONDI SC et al.: Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes. Nat. Genet (2005) 37(8):878-882.
5. CHEOK MH, YANG W, PUI CH et al.: Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nat. Genet. (2003) 34(1):85-90.
6. KAGER L, CHEOK M, YANG W et al.: Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. J. Clin. Invest. (2005) 115(1):110-117.
7. ZAZA G, CHEOK M, YANG W et al.: Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment. Blood (2005) 106(5):1778-1785.
8. TEUFFEL O, DETTLING M, CARIO G et al.: Gene expression profiles and risk stratification in childhood acute lymphoblastic leukemia. Haematologica (2004) 89(7):801-808.
9. MCLEOD HL, LIN JS, SCOTT EP, PUI CH, EVANS WE: Thiopurine methyltransferase activity in American white subjects and black subjects. Clin. Pharmacol. Ther. (1994) 55(1):15-20.
10. OTTERNESS D, SZUMLANSKI C, LENNARD L et al.: Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin. Pharmarol. Ther. (1997) 62(1):60-73.
11. LAROVERE LE, DE KREMER RD, LAMBOOY LH, DE ABREU RA: Genetic polymorphism of thiopurine S-methyltransferase in Argentina. Ann. Clin. Biochem. (2003) 40(Part 4):388-393.
12. INDJOVA D, ATANASOVA S, SHIPKOVA M et al.: Phenotypic and genotypic analysis of thiopurine S-methyltransferase polymorphism in the bulgarian population. Ther. Drug Monit. (2003) 25(5):631-636.
13. COULTHARD SA, HALL AG: Recent advances in the pharmacogenomics of thiopurine methyltransferase. Pharmacogenomics J. (2001) 1(4):254-261.
14. HON YY, FESSING MY, PUI CH et al.: Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. Hum. Mol. Genet. (1999) 8(2):371-376.
15. HIRATSUKA M, INOUE T, OMORI F, AGATSUMA Y, MIZUGAKI M Genetic analysis of thiopurine methyltransferase polymorphism in a Japanese population. Mutat. Res. (2000) 448(1):91-95.
16. ZHANG JP, GUAN YY, WU JH, JIANG WQ, HUANG M Genetic polymorphism of the thiopurine S-methyltransferase of healthy Han Chinese. Ai. Zheng(2003) 22(4):385-388.
17. SRIMARTPIROM S, TASSANEEYAKUL W, KUKONGVIRIYAPAN V, TASSANEEYAKUL W. Thiopurine S-methyltransferase genetic polymorphism in the Thai population. Br. J. Clin. Pharmacol. (2004) 58(1):66-70.
18. RELLING MV HANCOCK ML, RIVERA GK et al.: Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyttransferase gene locus. J. Natl. Cancer Inst. (1999) 91(3):2001-2008.
19. RELLING MV, PUI CH, CHENG C, EVANS WE: Thiopurine methyltransferase in acute lymphoblastic leukemia. Blood (2006) 107(2):843-844.
20. EVANS WE, HON YY, BOMGAARS L et al.: Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J. Clin. Oncol. (2001) 19(8):2293-2301.
21. RELLING MV, RUBNITZ JE, RIVERA GK et al.: High incidence of secondary brain tumours. after radiotherapy and antimetabolites. Lancet (1999) 354(9172):34-39.
22. RELLING MV, YANISHEVSKI Y, NEMEC J et al.: Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia (1998) 12(3):346-352.
23. STANULLA M, SCHAEFFELER E, FLOHR T et al.: Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA (2005) 293(12):1485-1489.
24. MCLEOD HL, COULTHARD S, THOMAS AE et al.: Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia. Br. J. Haematol. (1999) 105(3):696-700.
25. RELLING MV, HANCOCK ML, BOYETT JM, PUI CH, EVANS WE: Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood (1999) 93(9):2817-2823.
26. CHEUNG ST, ALLAN RN: Mistaken identity: misclassification of TPMT phenotype following blood transfusion. Eur. J. Gastroenterol. Hepatol. (2003) 15(11):1245-1247.
27. MCLEOD HL, RELLING MV, LIU Q, PUI CH, EVANS WE et al.: Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood (1995) 85(7):1897-1902.
28. SCHAEFFELER E, FISCHER C, BROCKMEIER D et al.: Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics (2004) 14(7):407-417.
29. KRYNETSKIY EY, EVANS WE: Closing the gap between science and clinical practice: the thiopurine S-methyltransferase polymorphism moves forward. Pharmacogenetics (2004) 14(7):395-396.
30. PUI CH, RELLING MV, SANDLUND JT et al.: Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia. Ann. Hematol. (2004) 83(Suppl. 1):S124-S126.
31. GOYETTE P, SUMNER JS, MILOS R et al.: Human methylenetetrahydrofolate reductase: isolation of cDNA mapping and mutation identification. Nat. Genet. (1994) 7(4):551.
32. BOTTO LD, YANG Q: 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. Am. J. Epidemiol. (2000) 151(9):862-877.
33. ROBIEN K, ULRICH CM: 5,10-Methylenetetrahydrofolate reductase polymorphisms and leukemia risk: a HuGE mini review. Am. J. Epidemiol. (2003) 157(7):571-582.
34. KRAJINOVIC M, LEMIEUX-BLANCHARD E, CHIASSON S et al.: Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia. Pharmacogenomics J. (2004) 4(1):66-72.
35. APLENC R, THOMPSON J, HAN P et al.: Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. Cancer Res. (2005) 65(6):2482-2487.
36. KISHI S, GRIENER J, CHENG C et al.: Homocysteine, pharmacogenetics, and neurotoxiciry in children with leukemia. J. Clin. Oncol. (2003) 21(16):3084-3091.
37. JAZBEC J, KITANOVSKI L, APLENC R. DEBELJAK M, DOLZAN V. No evidence of association of methylenetetrahydrofolate reductase polymorphism with occurrence of second neoplasms after treatment of childhood leukemia. Leuk. Lymphoma (2005) 46(6):893-897.
38. SHIMASAKI N, MORI T, SAMEJIMA H et al.: Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma. J. Pediatr. Hematol. Oncol. (2006) 28(2):64-68.
39. KRAJINOVIC M, ROBAEY P, CHIASSON S et al.: Polymorphisms of genes controlling homocysteine levels and IQ score following the treatment for childhood ALL. Pharmacogenomics (2005) 6(3):293-302.
40. CHIUSOLO P, REDDICONTO G, CASORELLI I et al.: Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. Ann. Oncol. (2002) 13(12):1915-1918.
41. ULRICH CM, YASUI Y, STORB R et al.: Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood (2001) 98(1):231-234.
42. COSTEA I, MOGHRABI A, LAVERDIERE C, GRAZIANI A, KRAJINOVIC M et al.: Folate cycle gene variants and chemotherapy toxicity in pediatric patients with acute lymphoblastic leukemia. Haematologica (2006).
43. KANEDA S, NALBANTOGLU J, TAKEISHI K et al.: Structural and functional analysis of the human thymidylate synthase gene. J. Biol. Chem. (1990) 265(33):20277-20284.
44. MARSH S, COLLIE-DUGUID ES, LI T, LIU X, MCLEOD HL: Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics (1999) 58(3):310-312.
45. KRAJINOVIC M, COSTEA I, CHIASSON S: Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia. Lancet (2002) 359(9311):1033-1034.
46. KRAJINOVIC M, COSTEA I, PRIMEAU M, DULUCQ S, MOGHRABI A: Combining several polymorphisms of thymidylate synthase gene for pharmacogenetic analysis. Pharmacogenomics J. (2005) 5(6):374-380.
47. COSTEA I, MOGHRABI A, KRAJINOVIC M: The influence of cyclin D1 (CCND1) 870A>G polymorphism and CCND1-thymidylate synthase (TS) gene-gene interaction on the outcome of childhood acute lymphoblastic leukaemia. Pharmacogenetics (2003) 13(9):577-580.
48. ROCHA JC, CHENG C, LIU W et al.: Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood (2005) 105(12):4752-4758.
49. LAUTEN M, ASGEDOM G, WELTE K, SCHRAPPE, M, STANULLA M et al.: Thymidylate synthase gene polymorphism and its association with relapse in childhood B-cell precursor acute lymphoblastic leukemia. Haematologica (2003) 88(3):353-354.
50. RELLING MV, YANG W, DAS S et al.: Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia. J. Clin. Oncol. (2004) 22(19):3930-3936.
51. RADY PL, SZUCS S, MATALON RK et al.: Genetic polymorphism (G80A) of reduced folate carrier gene in ethnic populations. Mol, Genet. Metab. (2001) 73(3):285-286.
52. LAVERDIERE C, CHIASSON S, COSTEA I, MOGHRABI A, KRAJINOVIC M et al.: Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood (2002) 100(10):3832-3834.
53. FUJITA K: Cytochrome P450 and anticancer drugs. Curr. Drug Metab. (2006) 7(1):23-37.
54. GUENGERICH FP: Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J. (2006) 8(1):E101-E111.
55. RODRIGUEZ-ANTONA C, INGELMAN-SUNDBERG M: Cytochrome P450 pharmacogenetics and cancer. Oncogene (2006) 25(11):1679-1691.
56. SOLUS JF, ARIETTA BJ, HARRIS JR, et al.: Genetic variation in eleven Phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics (2004) 5(7):895-931.
57. XIE HG, WOOD AJ, KIM RB, STEIN CM, WILKINSON GR. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics (2004) 5(3):243-272.
58. KESHAVA C, MCCANLIES EC, WESTON A: CYP3A4 polymorphisms - potential risk factors for breast and prostate cancer: a HuGE review. Am. J. Epidemiol. (2004) 160(9):825-841.
59. APLENC R, GLATFELTER W, HAN P et al.: CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia. Br. J. Haematol. (2003) 122(2):240-244.
60. FLEURY I, PRIMEAU M, DOREAU A et al.: Polymorphisms in genes involved in the corticosteroid response and the utcome of childhood acute lymphoblastic leukemia. Am. J. Pharmacogenomics (2004) 4(5):331-341.
61. FELIX CA, WALKER AH, LANGE BJ et al.: Association of CYP3A4 genotype with treatment-related leukemia. Proc. Natl. Acad. Sci. USA (1998) 95(22):13176-13181.
62. BLANCO JG, EDICK MJ, HANCOCK ML et al.: Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies. Pharmacogenetics (2002) 12(8):605-611.
63. KRAJINOVIC M, LABUDA D, SINNETT D: Childhood acute lymphoblastic leukemia: genetic determinants of susceptibility and disease outcome. Rev. Environ. Health (2001) 16(4):263-279.
64. KRAJINOVIC M, LABUDA D, MATHONNET G et al.: Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukemia. Clin. Cancer Res. (2002) 8(3):802-810.
65. KRAJINOVIC M, LABUDA D, SINNETT D: Glucathione S-transferase P1 genetic polymorphisms and susceptibility to childhood acute lymphoblastic leukaemia. Pharmacogenetics (2002) 12(8):655-658.
66. CHEN CL, LIU Q, PUI CH et al.: Higher frequency of glutathione S-transferase deletions in black children with acute lymphoblastic leukemia. Blood (1997) 89(5):1701-1707.
67. DAVIES SM, BRATIA S, ROSS JA et al.: Glutathione S-transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia. Blood (2002) 100(1):67-71.
68. PEMBLE S, SCHROEDER KR, SPENCER SR et al.: Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem. J. (1994) 300(Part 1):271-276.
69. LANDI S: Mammalian class theta GST and differential susceptibility to carcinogens: a review. Mutat. Res. (2000) 463(3):247-283.
70. STANULLA M, SCHRAPPE M, BRECHLIN AM, ZIMMERMANN M, WELTE K: Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study. Blood (2000) 95(4):1222-1228.
71. TAKANASHI M, MORIMOTO A, YAGI T et al.: Impact of glutathione S-transferase gene deletion on early relapse in childhood B-precursor acute lymphoblastic leukemia. Haematologica (2003) 88(11):1238-1244.
72. MEISSNER B, STANULLA M, LUDWIG WD, et al.: The GSTT1 deletion polymorphism is associated with initial response to glucocorticoids in childhood acute lymphoblastic leukemia. Leukemia (2004) 18(11):1920-1923.
73. ANDERER G, SCHRAPPE M, BRECHLIN AM et al.: Polymorphisms within glutathione S-transferase genes and initial response to glucocorticoids in childhood acute lymphoblastic leukaemia. Pharmacogenetics (2000) 10(8):715-726.
74. STANULLA M, SCHAFFELER E, ARENS S et al.: GSTP1 and MDR1 genotypes and central nervous system relapse in childhood acute lymphoblastic leukemia. Int. J. Hematol. (2005) 81(1):39-44.
75. JAZBEC J, APLENC R, DOLZAN V DEBELJAK M, JEREB B: GST polyrnorphisms and occurrence of second neoplasms after treatment of childhood leukemia. Leukemia (2003) 17(12):2540-2542.
76. CASCORBI I, GERLOFF T, JOHNE A et al.: Frequency of single nucleotide polymorphisms in the P-glycoprotein drug ransporter MDR1 gene in white subjects. Clin. Pharmacol. Ther. (2001) 69(3):169-174.
77. JAMROZIAK K, BALCERCZAK E, MLYNARSKI W, MIROWSKI M, ROBAK T: Distribution of allelic variants of functional C3435T polymorphism of drug transporter MDR1 gene in a sample of Polish population. Pol. J. Pharmacol. (2002) 54(5):495-500.
78. SCHAEFFELER E, EICHELBAUM M, BRINKMANN U et al.: Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet (2001) 358(9279):383-384.
79. JAMROZIAK K, MLYNARSKI W, BALCERCZAK E et al.: Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur. J. Haematol. (2004) 72(5):314-321.
80. PLASSCHAERT SL, GRONINGER E, BOEZEN M et al.: Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia. Clin. Pharmacol. Ther. (2004) 76(3):220-229.
81. STANULLA M, SCHRAUDER A, WELTE K, SCHRAPPE M: Tumor necrosis factor and lymphotoxin-alpha genetic polymorphisms and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study of patients treated with BFM therapy. BMC Blood Disord. (2001) 1(1):2.
82. LAUTEN, M, MATTHIAS T, STANULLA M et al.: Association of initial response to prednisone treatment in childhood acute lymphoblastic leukaemia and polymorphisms within the tumour necrosis factor and the interleukin-10 genes. Leukemia (2002) 16(8):1437-1442.
83. JAISWAL AK, BELL DW, RADJENDIRANE V, TESTA JR et al.: Localization of human NQO1 gene to chromosome 16q22 and NQO2-6p25 and associated polymorphisms. Pharmacogenetics (1999) 9(3):413-418.
84. ZIINO O, D'URBANO LE, DE BENEDETTI F et al.: The MIF-173G/C polymorphism does not contribute to prednisone poor response in vivo in childhood acute lymphoblastic leukemia. Leukemia (2005) 19(12):2346-2347.
85. NEBERT DW, ROE AL, VANDALE SE, BINGHAM E, OAKLEY GG: NAD(P)H:quinone oxidoreductase (NQO1) polymorphism, exposure to benzene, and predisposition to disease: a HuGE review. Genet. Med. (2002) 4(2):62-70.
86. DE BENEDETTI F, MEAZZA C, VIVARELLI M, et al.: Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. (2003) 48(5):1398-1407.
87. KRAJINOVIC M, SINNETT H, RICHER C, LABUDA D SINNETT D: Role of NQO1, MPO and CYP2E1 genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Int. J. Cancer (2002) 97(2):230-236.